anti-HAV

anti-HAV

Serum antibody to hepatitis A virus. The presence of anti-HAV in the blood is an indicator either of a successful immune response to vaccination or a current or previous hepatitis A infection.
References in periodicals archive ?
A case was defined as an anti-HAV immunoglobulin M (IgM)-positive diagnosis in a person who had eaten at the restaurant three or more times during the 6-week period before onset of illness.
All five employees of the market denied having hepatitis symptoms; four of these were tested and were negative for IgM antibody to hepatitis A virus (IgM anti-HAV).
[13] Serum samples were tested for anti-HAV total antibodies (IgG and immunoglobulin M (IgM)) using a manual enzyme immunoassay (Siemens Enzygnost anti-HAV), as per Siemens protocol.
Serology for viral hepatitis suggested acute hepatitis A infection (anti-HAV IgM positive.) Laboratory data at the time of admission were total bilirubin 3.9 mg/dl, bilirubin direct 2.65 mg/dl, bilirubin indirect 1.25 mg/dl, ALT/SGPT 1690 u/l, ALP 1310 u/l, gGT 196 u/l, Hb 12g/dl, total leucocyte count 5,400/ul, neutrophils 52%, lymphocytes 44% and platelets 242,000/ul.
Detectable antibodies persist for at least 20 years after HepA vaccination in childhood (9), and antibodies persist for an estimated 40 years or longer based on mathematical modeling and anti-HAV kinetic studies (9).
Two tests used for this performance indicator included superfluous repeat orders for a genetic test (factor V Leiden [FVL]) and unnecessary repeat serologic testing for total anti-hepatitis A virus antibody (anti-HAV) when a previous test result was positive, indicating lifelong immunity.
This study evaluated the single-dose schedule of anti-HAV vaccination adopted by the Brazilian government in a small city in the state of Mato Grosso, Central Brazil.
Literature lacks data on the seroprevalence of antibodies to HAV (anti-HAV) among workers in wastewater treatment plants (WWTPs) in Bulgaria.
The results of a total of 19862 cases for whom anti-HAV IgG and anti-HAV IgM were requested were retrospectively evaluated, and 4211 cases at 18 years of age and under were included in this study.
(6) reported that in the adult population, the anti-HAV immunoglobulin M positivity prevalence rate is 1.2% at an age range of 17-29 years old.